Wu Rongrong, Dong Lvhua, Mao Huajie, Wang Jianjun, Ma Dijiang, Sun Jianing
Rongrong Wu, Department of ENT and Head & Neck Surgery, Linhai Second People's Hospital, Taizhou 317016, Zhejiang, China.
Lvhua Dong, Department of ENT and Head & Neck Surgery, Linhai Second People's Hospital, Taizhou 317016, Zhejiang, China.
Pak J Med Sci. 2022 Sep-Oct;38(7):1888-1892. doi: 10.12669/pjms.38.7.5561.
To investigate the clinical effect of posterior nasal nerve combined with anterior ethmoid neurotomy in the treatment of moderate to severe persistent allergic rhinitis.
Thirty patients with moderate to severe persistent allergic rhinitis admitted to Linhai Second People's Hospital from August 2019 to June 2020 were selected as subjects for prospective study and design. All patients underwent posterior nasal neurotomy and anterior ethmoid neurotomy simultaneously. Subsequently, the efficacy of all patients at 0.5 and one year postoperatively was compared. Their symptom score preoperatively and one year postoperatively as well as their preoperative and postoperative quality of life score were compared, and related adverse reactions were collected.
The curative effect ratio was 60% after 0.5 years and 90.0% after one year, showing a significant increase ( =12.000, P=0.007<0.05). The symptom score at one year postoperatively (1.15±0.32) was lower than that preoperatively (2.12±0.58), with a statistically significant difference (t=11.351, P=0.000<0.05); In terms of quality of life, nasal symptoms, ocular symptoms, practical difficulties, sleep disorders, emotional disorders and other symptoms were lower than those preoperatively, with statistically significant differences (P<0.05). Adverse reactions occurred in 4 patients (13.33%), but were eliminated after treatment.
Posterior nasal nerve combined with anterior ethmoid neurotomy is a safe and reliable surgical method for the treatment of moderate to severe persistent allergic rhinitis, boasting a variety of benefits such as symptomatic relief, improved quality of life, and reduced adverse reactions, which is worthy of clinical promotion.
探讨鼻后神经联合筛前神经切断术治疗中重度持续性变应性鼻炎的临床效果。
选取2019年8月至2020年6月临海市第二人民医院收治的30例中重度持续性变应性鼻炎患者作为前瞻性研究对象并进行设计。所有患者均同时接受鼻后神经切断术和筛前神经切断术。随后，比较所有患者术后0.5年和1年时的疗效。比较他们术前和术后1年的症状评分以及术前和术后的生活质量评分，并收集相关不良反应。
0.5年后有效率为60%，1年后为90.0%，呈显著升高（χ² = 12.000，P = 0.007 < 0.05）。术后1年症状评分为（1.15±0.32），低于术前（2.12±0.58），差异有统计学意义（t = 11.351, P = 0.000 < 0.05）；在生活质量方面，鼻部症状、眼部症状、实际困难、睡眠障碍、情绪障碍等症状均低于术前，差异有统计学意义（P < 0.05）。4例患者（13.33%）出现不良反应，但治疗后消失。
鼻后神经联合筛前神经切断术是治疗中重度持续性变应性鼻炎安全可靠的手术方法，具有缓解症状、改善生活质量、减少不良反应等多种益处，值得临床推广。
